9 directorsName after signing inVisible after signing in and 8 others
Owners4 names in the annual accounts
15.55%Hidden nameVisible after signing in and 2 others
Documentsfilings and deeds
30-06-202631 days before the deadline
2025abbreviated format
Gross margin from €32,440 to €55,321Loss of €2.9mStaff from 24 FTE to 16.8 FTEName hiddenVisible after signing in resigns as director26-11Capital increase · Amendment of the articles21-11Capital increase · Amendment of the articles11-09
Lower net result than 91% of companies in research and development. The sector median is €454, over 344 companies.
Checked score
Checked score
The higher the Checked score (0 to 100), the smaller the chance that the company goes bankrupt within twelve months. That chance sets the band, from Critical to Excellent, and within the band how the company does against its sector peers counts too. With a low score, agree a shorter payment term, an advance or security.
XXVisible after signing in
HiddenVisible after signing in
Bankruptcy probability within 12 months
Bankruptcy probability
It is the chance that the company goes bankrupt within twelve months, estimated from the registers, the annual accounts and the Belgian Official Gazette. At 0.2%, about 2 in 1,000 comparable companies go bankrupt. The higher it is, the shorter the payment term to agree.
XXVisible after signing in
Financial strength
Financial strength
Financial strength measures the balance sheet and the results with three figures out of 100 from the latest annual accounts: solvency, liquidity and profitability. It does not directly set the Checked score's band. How the company does against its sector peers on these and on growth does count for its place within the band.
XXVisible after signing in
XXVisible after signing in
XXVisible after signing in
Score breakdown
Visible after signing inVisible after signing in
Comparable companies, two years later
In July 2024, 375 companies had the same profile as BOTALYS has now. Each dot is one company, two years later.
91.7%
were still trading
7.2%
stopped another way
1.1%
went bankrupt
Small
10 to 20 years old
solvency 30% or more
a loss of 10% of the balance sheet or more
Test of the method
The method was tested on the 497,894 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.7% would go bankrupt within 24 months. In fact 1.8% went bankrupt.
The companies in ten equal groups, from the lowest to the highest expected share
Group
Expected
Actual
1
0.2%
0.2%
2
0.4%
0.5%
3
0.6%
0.6%
4
0.7%
0.8%
5
0.9%
1.0%
6
1.4%
1.6%
7
1.7%
1.8%
8
1.9%
2.0%
9
3.1%
3.3%
10
5.9%
6.4%
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 375 companies, not a prediction for BOTALYS. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit verdict
The credit verdict says how much credit you can give the company on open account. “Acceptable” means normal terms, “With conditions” means limiting the amount or the term. “Not advised” means asking for payment up front.
Visible after signing inVisible after signing in
Credit check for an amount and term of your choice
Name hiddenVisible after signing in 15.55%score XXVisible after signing inequity €4.98bn (2025) · annual accounts 2025 of Name after signing inVisible after signing in
Name hiddenVisible after signing in 7.92%score XXVisible after signing inequity €7.7m (2025) · annual accounts 2025 of Name after signing inVisible after signing in
Name after signing inVisible after signing in resigns as director
General meeting of 09-05-2025 · Gazette deed
Capital increase · Amendment of the articles
The capital rose from €6,954,703.31 to €9,894,927.47, with 422,446 new shares · The capital fell from €9,894,927.47 to €4,179,541.13 · Contribution of €2,940,224.16 · General meeting of 12-11-2025 · Gazette deed
Capital increase · Amendment of the articles
The capital rose from €5,992,851.35 to €6,234,975.63, with 51,958 new shares · The capital rose from €6,234,975.63 to €6,439,433.13, with 43,875 new shares · The capital rose from €6,439,433.13 to €6,861,307.59, with 90,531 new shares · General meeting of 27-08-2025 · Gazette deed
3 directors appointed, 2 reappointments, 1 statutory auditor reappointedName hiddenVisible after signing in, Hidden nameVisible after signing in and Name after signing inVisible after signing in (statutory auditor) reappointed · Name hiddenVisible after signing in, Hidden nameVisible after signing in (independent director) and Name after signing inVisible after signing in appointed · Name hiddenVisible after signing in acts as permanent representative · General meeting of 16-06-2025 · Gazette deed
Sector peers are the companies with the same activity (NACE code) and, where stated, the same size, that the company is compared with. A percentile says how many of them do worse.
These companies have the same main activity as BOTALYS: research and development on biotechnology (NACE 72101). They are comparable in size and age: total assets between €3.8m and €9.6m, founded between 2003 and 2016.
BOTALYS files the abbreviated format. That format states no turnover. The gross margin rose from €9,081 in 2012 to €55,321 in 2025.
In July 2024, three directors stepped down. In October 2022, the Official Gazette published the appointment of Name hiddenVisible after signing in as managing director.
The company number of BOTALYS is 0834.134.177. The VAT number is the same number with BE in front: BE 0834.134.177.
Where is BOTALYS based?
The registered office is at Avenue des Artisans 8, 7822 Ath.Company details
What does BOTALYS do?
According to the KBO register, the main activity is research and development on biotechnology (NACE 72101).
What is the legal form of BOTALYS?
BOTALYS is a public limited company (NV).
When was BOTALYS founded?
BOTALYS was founded on 01-03-2011.
Is BOTALYS still active?
Yes, BOTALYS is an active enterprise in the KBO register.
How many employees does BOTALYS have?
BOTALYS had an average of 16.8 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
Which joint committee does BOTALYS fall under?
In its 2025 annual accounts, BOTALYS states joint committee 220 (White-collar workers in the food industry).
What is the turnover of BOTALYS?
The turnover in financial year 2025 is about €160,000. This figure is estimated from the gross margin of €55,321 and 992 comparable companies of the same size. It probably lies between €95,000 and €320,000. It is a rough estimate.
Is BOTALYS profitable?
In financial year 2025, BOTALYS made a loss of €2.9m.
Where can I find the annual accounts of BOTALYS?
BOTALYS filed 14 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of BOTALYS due?
BOTALYS must file the annual accounts for financial year 2026 by 31-07-2027.Timeline